

Accepted Manuscript

Public Health

Access to Care in Rare Liver Diseases: New Challenges and New Opportunities

David Jones, Ekkehard Sturm, Ansgar W. Lohse

PII: S0168-8278(17)32423-6

DOI: <https://doi.org/10.1016/j.jhep.2017.11.004>

Reference: JHEPAT 6742

To appear in: *Journal of Hepatology*


Received Date: 29 June 2017

Revised Date: 12 October 2017

Accepted Date: 1 November 2017

Please cite this article as: Jones, D., Sturm, E., Lohse, A.W., Access to Care in Rare Liver Diseases: New Challenges and New Opportunities, *Journal of Hepatology* (2017), doi: <https://doi.org/10.1016/j.jhep.2017.11.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Access to Care in Rare Liver Diseases: New Challenges and New Opportunities

David Jones^{1,2}, Ekkehard Sturm^{1,3} & Ansgar W. Lohse^{1,4}

*RARE-LIVER European Reference Network*¹, *Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, UK*², *University Children's Hospital, Tübingen, Germany*³ & *Dept of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany*⁴

Correspondence

Professor David Jones
Institute of Cellular Medicine
4th Floor William Leech Building
Medical School
Framlington Place
Newcastle upon Tyne
NE20 0SU

Phone: +44 191 208 7572
E-Mail: David.Jones@ncl.ac.uk

Acknowledgement

We are grateful to Dr. Anneke Werk for help in compiling the manuscript and in the underpinning literature review.

Word Count

4711

Tables

3

Figures

1

Key Words

Rare disease, transitional care, care delivery, genetic disease

Conflict of Interest

Dr. Jones reports grants, personal fees and other from Intercept, other from GSK, other from Novartis, other from Cymabay, other from FFPharma, other from Shire, grants and other from Pfizer, outside the submitted work.

Dr. Lohse reports a pending patent on SLA/LP antibody testing pending.

Dr Sturm reports consultancy for Albireo and Silence Therapeutics and, travel support from Alexion, Astellas and Albireo.

Financial Support

This review piece had no financial support

Author Contribution

DJ and AL contributed equally to the original draft of the Manuscript. ES added additional key elements related to paediatric practice at the resubmission stage. All authors approved the final version.

Download English Version:

<https://daneshyari.com/en/article/8729268>

Download Persian Version:

<https://daneshyari.com/article/8729268>

[Daneshyari.com](https://daneshyari.com)